Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)

Martin T. Lowy*, J. Frank Nash, Herbert Y. Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone- independent mechanism.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalEuropean Journal of Pharmacology
Volume163
Issue number1
DOIs
StatePublished - Apr 12 1989

Keywords

  • 3,4-Methylenedioxymethamphetamine (MDMA)
  • 5-Hydroxytryptamine
  • Corticosterone
  • Glucocorticoid receptors
  • Neurotoxicity
  • Striatum

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)'. Together they form a unique fingerprint.

Cite this